Search results
Results from the Think 24/7 Content Network
MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.
3,4-Methylenedioxyamphetamine (also known as MDA and sass) is an empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled ...
Mephedrone, also known as 4-methylmethcathinone, 4-MMC, and 4-methylephedrone, is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include drone, [5] M-CAT, [6] White Magic, [7] meow meow and bubble. [8] It is chemically similar to the cathinone compounds found in the Khat plant of eastern Africa.
These three stocks should deliver for investors. 1. Palantir Technologies. At first glance, investors might assume they've missed out on Palantir Technologies (NYSE: PLTR). The stock is up ...
Companies driving the AI boom have seen their stock prices rise rapidly in the past 18 months. For instance, an investment of $10,000 in shares of Nvidia (NASDAQ: NVDA) at the beginning of 2023 is ...
Artificial intelligence (AI) is a key driver of stock market returns right now. ... In other words, this company is delivering the results to back up the 156% year-to-date gain in its stock price.
5-Iodo-2-aminoindane ( 5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine. [2] It was developed in the 1990s by a team led by David E. Nichols at Purdue University. [3] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans. [3] Unlike related aminoindane derivatives like MDAI ...
MEAI ( 5-methoxy-2-aminoindane or 5-MeO-AI or Chaperon) belongs to the indane family of molecules. Its molecular structure was first mentioned implicitly in a markush structure schema appearing in a patent from 1998. [1] It was later explicitly and pharmacologically described in a peer reviewed paper in 2017 by David Nutt and Ezekiel Golan et ...